Recent Advances in Inflammatory and Infectious Skin Diseases (Second Edition)

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 10 June 2025 | Viewed by 632

Special Issue Editors


E-Mail
Guest Editor
Dermatology and Venereology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
Interests: skin and mucosal infections; sexually transmitted infections; infectious exanthems; human papillomaviruses; syphilis
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
DISSAL, Section of Dermatology, University of Genoa, Ospedale Policlinico San Martino IRCCS, Genova, Italy
Interests: dermatology; infectious skin disease; inflammatory skin disease
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Unit of Dermatology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy
Interests: psoriasis; biologic drugs; inflammatory skin diseases

Special Issue Information

Dear Colleagues,

Inflammatory skin diseases represent the largest class of skin disease, affecting up to 20-25% of the population at all stages of life. Among inflammatory skin diseases, atopic dermatitis in particular causes a high disease burden, and encompasses also the pediatric field, affecting up to 30% of the pediatric population, as well as 2-10% of adults. In addition, other eczematous diseases are exhibited, such as seborrheic dermatitis and psoriasis, as well as lichen and lichenoid dermatoses, urticaria and urticarial rashes, hidradenitis suppurativa, acne, rosacea, autoimmune diseases, drug reactions and reactions to toxins. These represent only part of the vast number of inflammatory skin diseases that are the primary focus of this Special Issue, which includes a discussion of their clinical presentation, either acute or more frequently chronic, and their ability to be characterized by recurrent relapses and acute flare-ups. In this Special Issue, the submission of articles providing a detailed outline of the pathogenetic mechanisms involved, either autoimmune or in response to infectious diseases, as well as these diseases’ complications, diagnosis and therapy, is welcome. Inflammatory dermatoses, especially if chronic, highly impact the life quality of patients and still present many unsatisfied needs; therefore, continuous therapeutic evolution deserves in-depth debate and space in this  Special Issue.

As for infectious diseases of the skin, these are indeed closely connected with cutaneous inflammatory diseases. In fact, there are many systemic infections that may cause inflammatory skin conditions: among the viral infections, human herpesvirus 6 and/or 7 are responsible for the exanthema subitum and their reactivation is the cause of pityriasis rosea; and among the bacterial infections, Treponema pallidum causes an inflammatory cutaneous manifestation known as “roseola syphilitica”.

Moreover, several common inflammatory diseases of the skin can be triggered or worsened by infections (guttate psoriasis, atopic dermatitis and others).

Following the success of the first edition of “Recent Advances in Inflammatory and Infectious Skin Diseases” (https://www.mdpi.com/journal/jcm/special_issues/222106OW3I), a second edition of this Special Issue is announced here with the aim to provide an update on the most recent research in the field of inflammatory and infectious skin diseases and their possible interconnections, pathogenesis, complications, and therapies.

Dr. Giulia Ciccarese
Dr. Astrid Herzum
Dr. Paolo Romita
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • eczematous diseases
  • inflammatory skin diseases
  • chronic skin diseases
  • human herpesvirus
  • roseola syphilitica
  • psoriasis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 250 KiB  
Article
PAP-HPV Co-Testing in Anal Cancer Screening: An Italian Experience
by Luigi Pisano, Claudia Giachini, Martina Turco, Jacopo Farini, Filippo Caminati, Iacopo Giani, Claudio Elbetti, Simonetta Bisanzi, Stefania Cannistrà, Giampaolo Pompeo, Cristina Sani and Nicola Pimpinelli
J. Clin. Med. 2025, 14(7), 2186; https://doi.org/10.3390/jcm14072186 - 23 Mar 2025
Viewed by 417
Abstract
Background/Objectives: Squamous cell carcinoma of the anus (SCCA) remains a relatively rare form of cancer linked to high-risk human papillomavirus (HR-HPV) infection; however, its incidence has been increasing globally. Anal cytology and HR-HPV testing can identify precursors, though standardized screening guidelines are [...] Read more.
Background/Objectives: Squamous cell carcinoma of the anus (SCCA) remains a relatively rare form of cancer linked to high-risk human papillomavirus (HR-HPV) infection; however, its incidence has been increasing globally. Anal cytology and HR-HPV testing can identify precursors, though standardized screening guidelines are still lacking. This study aimed to assess the correlation between high-resolution anoscopy (HRA) findings and primary screening results through PAP-HPV co-testing in high-risk patients. Methods: A retrospective, single-center study was conducted collecting data from the joint multidisciplinary anal cancer clinic of Piero Palagi Hospital in Florence (Italy), between August 2019 and September 2022. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of anal cytology, HR-HPV testing, and PAP-HPV co-testing were assessed. Results: In 577 HRAs, histology revealed 31 AIN2+ lesions (5.4%) and 220 AIN1 lesions (38.1%), while 326 (56.5%) were negative. Cytology alone showed a sensitivity of 74.2% and specificity of 63.3% for AIN2+ lesions, while HR-HPV testing alone had a sensitivity of 96.8% and specificity of 38.1%. Co-testing demonstrated 100% sensitivity and a 100% NPV for AIN2+ lesions. Among men who have sex with men (MSM), no significant differences in outcomes were observed between HIV-positive and HIV-negative patients, likely reflecting similar high-risk behaviors and effective HIV treatments. Conclusions: Co-testing with anal cytology and HR-HPV testing provides the most reliable screening for high-grade lesions (AIN2+), surpassing the reliability of individual methods. Tailored co-testing strategies are crucial for early detection and effective prevention in high-risk groups. Full article
Back to TopTop